Enliven Therapeutics, Inc.

NASDAQ: ELVN · Healthcare · Biotechnology

PublicHQ Boulder, CO · BoulderCIK 0001672619Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 70DQ —GM —SS 59

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$103.7M

Employees

as of 2026-09-08

Market cap

$4.2B

as of 2026-09-08

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$103.7M-$103.7M2025

Operating income-$119.7M-$119.7M2025

Total assets$476.2M$476.2M2025

Liabilities$16.6M$16.6M2025

Equity$459.6M$459.6M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Enliven Therapeutics, Inc.’s financial profile?

Enliven Therapeutics, Inc. earned -$103.7M in FY2025 net income.

Peers · Healthcare

Celcuity Inc.——Edgewise Therapeutics, Inc.——Dyne Therapeutics, Inc.——Veradermics, Incorporated——Legend Biotech Corporation——Galera Therapeutics, Inc.——

Neighbors

Boulder →

Edgewise Therapeutics, Inc.——Infleqtion Inc——Solid Power, Inc.$17.9M37D Gores Holdings XI, Inc.——Gloo Holdings, Inc.$94.7M31D CEA Industries Inc. Common Stock$26.4M65B

Key facts

CEORichard A. Fair

SectorHealthcare

IndustryBiotechnology

HeadquartersBoulder, CO

ExchangeNASDAQ: ELVN

Employees67

IPO date2020-03-12

Latest filings

8-K2026-10-14 10-Q2026-08-05 8-K2026-08-05 8-K2026-06-12 8-K2026-06-11 8-K2026-06-10 10-Q2026-05-07 8-K2026-05-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.